EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma

Gabriele Gugliotta, Lisa Argnani, Martina Cantelli, Antonio Pinto iD, Ausilia Gorgone, Francesco Piazza iD, Claudio Fozza iD, Vincenza Fernanda Fesce, Fabrizio Marino, Melania Celli, Elsa Pennese, Francesco Gaudio und 10 weitere

American Journal of Hematology · 2026-07 · 101 (7) · 1527-1537

DOI: 10.1002/ajh.70317 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 10.04.2026. Verfasst von Gabriele Gugliotta und 21 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Mediastinal Neoplasms, Immune Checkpoint Inhibitors, Lymphoma, B-Cell. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Italian Ministry of Health, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of immune checkpoint inhibitors (ICIs) has deeply improved the outcome of relapsed or refractory (R/R) primary mediastinal B‐cell lymphoma (PMBCL) patients. However, real‐world data are still limited, and several aspects, including the need for consolidation strategies, remain to be fully elucidated. We report the results of the multicenter Italian retrospective observational PRIMICI study on R/R PMBCL patients treated with ICIs in a real‐life (off‐label) setting. Seventy‐four patients, 42 treated with pembrolizumab and 32 with nivolumab‐brentuximab vedotin (nivo‐BV), were enrolled. The median follow‐up was 34 months. The best overall response and complete response (CR) rates were 64% ( n = 50) and 50% ( n = 37), respectively. Of the 37 patients in CR, 11 received a consolidation treatment and 26 patients continued ICIs; CR were stable, independently from the use of consolidation, with a 4‐year disease‐free survival of 100%. The estimated 5‐year progression‐free survival (PFS) and overall survival (OS) were 60.4% (95% confidence interval [C.I.] 48.3%–70.6%) and 77.5% (95% C.I. 65.8%–85.6%), respectively. Nivo‐BV was associated with faster and higher response rates and better OS compared to pembrolizumab. OS significantly improved after 2020 due to the use of salvage treatment with CAR T‐cells. In conclusion, this study supported the safety and effectiveness of pembrolizumab or nivo‐BV as a salvage therapy in R/R PMBCL patients. Importantly, the chance to obtain long‐lasting responses, regardless of the use of a consolidation treatment, indicates that ICIs may be used with a curative intent in a significant subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mediastinal NeoplasmsImmune Checkpoint InhibitorsLymphoma, B-CellHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultAntibodies, Monoclonal, HumanizedAged, 80 and overRecurrenceSalvage Therapy

Stichwörter der Autor:innen

brentuximab‐vedotinnivolumabpembrolizumabprimary mediastinal B‐cell lymphomarelapsed/refractory

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Università di Bologna, Bologna, Italy.
  • Ematologia Oncologica, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Napoli, Italy.
  • UOC Ematologia, ARNAS Garibaldi, Catania, Italy.
  • Hematology Unit, Department of Medicine, University of Padua, Padova, Italy.
  • Blood Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.

ORCID-Profile: Antonio Pinto, Francesco Piazza, Claudio Fozza, Pier Luigi Zinzani

Förderung

  • Italian Ministry of Health
  • Ministero della Salute

Zitieren

APA

Gugliotta, G., Argnani, L., Cantelli, M., Pinto, A., Gorgone, A., Piazza, F., Fozza, C., Fesce, V. F., Marino, F., Celli, M., Pennese, E., Gaudio, F., Lauzzana, P., Pezzullo, L., Lorenzo, S., Nierychlewska, P. M., Ceparano, G., Pane, F., Casadei, B., …, & Zinzani, P. L. (2026). A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma. American Journal of Hematology, 101(7), 1527-1537. https://doi.org/10.1002/ajh.70317

Vancouver

Gugliotta G, Argnani L, Cantelli M, Pinto A, Gorgone A, Piazza F, et al. A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma. American Journal of Hematology. 2026;101(7):1527-1537. doi:10.1002/ajh.70317

BibTeX
@article{Gugliotta2026,
  author = {Gugliotta, Gabriele and Argnani, Lisa and Cantelli, Martina and Pinto, Antonio and Gorgone, Ausilia and Piazza, Francesco and Fozza, Claudio and Fesce, Vincenza Fernanda and Marino, Fabrizio and Celli, Melania and Pennese, Elsa and Gaudio, Francesco and Lauzzana, Pietro and Pezzullo, Luca and Lorenzo, Sonya De and Nierychlewska, Paulina Maria and Ceparano, Giusy and Pane, Fabrizio and Casadei, Beatrice and Pellegrini, Cinzia and Romano, Claudia and Zinzani, Pier Luigi},
  title = {A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1527--1537},
  doi = {10.1002/ajh.70317}
}
Kostenlos starten →